A comparison of platelet function tests and thromboxane metabolites to evaluate residual platelet reactivity in patients with type 2 diabetes Original article

Main Article Content

Marek Postuła
Marek Rosiak
Agnieszka Kapłon-Cieślicka
Ewa Trzepla
Krzysztof J. Filipiak
Andrzej Członkowski
Grzegorz Opolski

Abstract

Background: Type 2 diabetes (T2DM) patients are at increased risk of cardiovascular events despite long-term acetylsalicylic acid (ASA) therapy. We aimed to compare the results obtained from two major platelet function point-of-care tests and thromboxane A2 metabolites in the assessment of the prevalence of high platelet reactivity (HPR) on ASA in T2DM patients.


Methods and results: The study cohort consisted of 262 T2DM patients who had been taking ASA tablets at the dose of 75 mg per day for at least 3 months for primary or secondary prevention of myocardial infarction. Platelet reactivity analyzes were performed using VerifyNow Aspirin and PFA-100 assays. Thromboxane A2 metabolites were also measured in serum and urine to assess cyclooxygenase-1 specific platelet reactivity inhibition. The prevalence of HPR varied according to the assay used: 35,4%, for PFA-100 using epinephrine as the agonist, 16,1%, for VerifyNow Aspirin Assay, and finally, 21,6% by measuring urinary 11-dehydro-thromboxane B2 and 9,8% measuring serum throboxane B2 concentrations. HPR were found in over 55% of patients based on at least one test, and in only 2,2% based on all performed tests. Results from these tests showed poor correlation and agreement among themselves.


Conclusion: Platelet function tests are not equally effective in measuring HPR and correlate poorly among themselves.

Downloads

Download data is not yet available.

Article Details

How to Cite
Postuła , M., Rosiak , M., Kapłon-Cieślicka , A., Trzepla , E., Filipiak , K. J., Członkowski , A., & Opolski , G. (2012). A comparison of platelet function tests and thromboxane metabolites to evaluate residual platelet reactivity in patients with type 2 diabetes. Cardiology in Practice, 6(2), 10-18. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1580
Section
Articles

References

1. Beckman J.A., Creager M.A., Libby P.: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
2. Yazbek N., Bapat A., Kleiman N.: Platelet abnormalities in diabetes mellitus. Coron. Artery Dis. 2003; 14: 365-71.
3. Natarajan A., Zaman A.G., Marshall S.M.: Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab. Vasc. Dis. Res. 2008; 5: 138-44.
4. Ferroni P., Basili S., Falco A., Davi G.: Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2004; 2: 1282-91.
5. DiChiara J., Bliden K.P., Tantry U.S. et al.: The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007; 56: 3014-9.
6. Evangelista V., de Berardis G., Totani L. et al.: Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J. Thromb. Haemost. 2007; 5: 2197-203.
7. Mortensen S.B., Larsen S.B., Grove E.L., Kristensen S.D., Hvas A.M.: Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thrombosis Res. 2010; 126: 318-22.
8. Ertugrul D.T., Tutal E., Yildiz M. et al.: Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2010; 95: 2897-901.
9. Fateh-Moghadam S., Plockinger U., Cabeza N. et al.: Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005; 42: 99-103.
10. Yazbek N., Bapat A., Kleiman N.: Platelet abnormalities in diabetes mellitus. Coron. Artery Dis. 2003; 14: 365-71.
11. Takahashi S., Ushida M., Komine R. et al.: Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thrombosis Res. 2007; 119(4): 517-24.
12. Frelinger A.L. 3rd, Furman M.I., Linden M.D. et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-96.
13. Blais N., Pharand C., Lordkipanidze M., Sia Y.K., Merhi Y., Diodati J.G.: Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb. Haemost. 2009; 102: 404-11.
14. Frelinger A.L., Li Y., Linden M.D. et al.: Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests. J. Thromb. Haemost. 2008; 6: 2035-44.
15. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W.: Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011; 22: 188-95.
16. Grove E.L., Hvas A.M., Johnsen H.L. et al.: A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb. Haemost. 2010; 103: 1245-53.
17. Gurbel P.A., Bliden K.P., DiChiara J. et al.: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-64.
18. Harrison P., Segal H., Blasbery K., Furtado C., Silver L., Rothwell P.M.: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-5.
19. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A., Diodati J.G.: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 2007; 28: 1702-8.
20. Davi G., Catalano I., Averna M. et al.: Thromboxane biosynthesis and platelet function in type II diabetes mellitus. NEJM 1990; 322: 1769-74.
21. Postula M., Kaplon-Cieslicka A., Rosiak M. et al.: Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J. Thromb. Haemost. 2011; 9: 2291-301.
22. Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., de Gaetano G.: Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb. Haemost. 2008; 99: 14-26.
23. Christie D.J., Kottke-Marchant K., Gorman R.T.: Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008; 19: 104-10.
24. Nielsen H.L., Kristensen S.D., Thygesen S.S., Mortensen J., Pedersen S.B., Grove E.L., Hvas A.M.: Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb. Res. 2008; 123: 267-73.
25. Capodanno D., Patel A., Dharmashankar K. et al.: Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv. 2011; 4: 180-7.
26. Angiolillo D.J., Shoemaker S.B., Desai B. et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-16.
27. Harrison P., Frelinger A.L. 3rd, Furman M.I., Michelson A.D.: Measuring antiplatelet drug effects in the laboratory. Thromb. Res. 2007; 120: 323-36.
28. Yassine H.N., Davis-Gorman G., Stump C.S., Thomson S.S., Peterson J., McDonagh P.F.: Clinical determinants of aspirin resistance in diabetes. Diabetes Res. Clin. Pract. 2010; 90: e19-21.
29. Tantry U.S., Mahla E., Gurbel P.A.: Aspirin resistance. Prog. Cardiovasc. Dis. 2009; 52: 141-52.
30. Maree A.O., Curtin R.J., Dooley M., Conroy R.M., Crean P., Cox D., Fitzgerald D.J.: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J. Am. Coll. Cardiol. 2005; 46: 1258-63.
31. Catella F., Healy D., Lawson J.A., Fitzgerald G.A.: 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proceedings of the National Academy of Sciences of the United States of America 1986; 83: 5861-5.
32. Patrignani P.: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb. Res. 2003; 110: 281-6.
33. Ferreira I.A., Mocking A.I., Feijge M.A. et al.: Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 417-22.
34. Michelson A.D.: Methods for the measurement of platelet function. Am. J. Card. 2009; 103: 20A-6A.